Klinge Pharma Gmbh

Lts Lohmann Therapie-systeme Gmbh + Co. Kg

Lts Lohmann Therapie Systeme Gmbh & Co.

Fritz Stanislaus

Thomas Hille

Gerhard Schneider

Hans-Joachim Huber

Hans-Rainer Hoffmann

Lothar Deurer

Thomas Profitlich

Axel Woschina

Artur Burger

Josef M Hofer

Kersten Walter

Axel Knoch

Axel Koch

Karl Schwitzer

Arnim Laicher

Gert-Ulfert Heese

Anita Lettenbichler

Transdermal therapeutic system for the administration of physostigmine

A new modification of Lifibrol is described with a melting point of 132.degree. C.-138.degree. C. particularly from 134.degree. C.-136.degree. C. and a primary peak in an IR spectrum at a wave number of 3,200-3,400, preferably 3,250-3,350. The new modification of Lifibrol (modification II) is distinguished in that it allows for good crystallization and, therefore, can be formulated without problems on a large industrial scale for tablets of acceptable size and high stability.

Lifibrol and its use

The present invention relates to a transdermal therapeutical system for the administration of physostigmine to the skin via a backing layer which is impermeable to active substances, an active substance deposit comprising at least one auxiliary agent with supporting and distributing function in the form of a textile fabric material, a matrix surrounding said deposit from all sides, and optionally a removable protective layer, the matrix of which comprises 10-90%-wt polymeric material selected from the group consisting of polymers on the basis of acrylate and/or methacrylate and esters of hydrogenated colophonium, 0-30%-wt softener on the basis of hydrocarbons and/or esters, and that the active substance deposit immediately after its production comprises 15-85%-wt of a 0.1-70%-wt physostigmine solution.

Transdermal therapeutical system with physostigmine as active component

The present invention relates to a transdermal therapeutical system for the administration of physostigmine to the skin via a cover layer which is impermeable to active substances, a pressure-sensitive adhesive reservoir layer, and optionally a removable protective layer, said reservoir layer consisting of 10-90% polymeric material selected from the groups consisting of block copolymers on the basis of styrene and 1,3-dienes, polyisobutylenes, polymers on the basis of acrylates and/or methacrylates and esters of hydrogenated colophonium, 0-30%-wt softeners on the basis of hydrocarbons and/or esters, and 0.1-20%-wt physostigmine.

Transdermal therapeutical system comprising physostigmine as active

A new pharmaceutical formulation as well as a process for its preparation are described, in which the active ingredient in one pharmaceutical form is present in retarded release form in one part, and in another part is present in a form resistant to gastric juices.

Pharmaceutical formulation as well as a process for its preparation

Growing community of inventors

Munich, Germany

Fritz Stanislaus